Vetter Embarks on a 300 Million Euro Investment Strategy for Further Development To its Manufacturing Sites and to make available Additional Manufacturing Capacities
By Business Wire News
Vetter has announced that in keeping with its commitment to providing customers with the manufacture of high quality drug products, the company will invest approximately 300 million euros to expand and upgrade its manufacturing facilities over an estimated five-year period. As a leading contract development and manufacturing organization, Vetter is continuously developing its manufacturing sites and techniques to prepare them for future needs and requirements. The upgrades are being driven by a changing healthcare market that is affected by issues such as ever-more complex molecules, smaller batch sizes, and increasing regulatory requirements.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20151001005755/en/
Structural work completed (Photo: Business Wire)
The first of the facility expansions are already ongoing at several of the company’s German locations including its ‘Ravensburg Vetter West’ center for visual inspection and logistics. Structural work for the facility enlargement, which will offer more than double of its current capacity, is completed with the site being on schedule to become fully operational in 2017. In addition, the Ravensburg Vetter South production site has also been designated for significant enlargements as is the Ravensburg Schuetzenstrasse facility where initial construction activities began in 2013. All three site expansions will result in additional capacities for drug product manufacturing and logistic sevices.
A central technology element of the planned upgrades will be the implementation of an in-house made improved restricted access barrier system (RABS) concept which will contribute to increased operational excellence in aseptic manufacturing. For decades, Vetter has relied on RABS as one of the two distinct technologies available today for its aseptic filling processes, the other being isolators. RABS achieves the sterility assurance level (SAL) required by regulatory authorities, and allows for rapid product change-over coupled with high safety. To better meet future industry trends in quality, safety and flexibility, a corporate project team has evolved this ‘Improved RABS concept’ by combining the advantages of isolator and RABS technology. The core of the approach is a uniquely fast, by today’s standards, 3-hour cycle and fully automated decontamination of the cleanroom using hydrogen peroxide (H2O2), resulting from an extremely high level of process innovation. Following a successful pilot project in a selected cleanroom the company will now implement this decontamination concept in all of its cleanrooms within the next years.
All of the planned activities are designed to meet future customer expectations and regulatory requirements at an early stage, maintaining a level of manufacturing excellence that customers have come to expect from Vetter. “We are continuously monitoring and reacting to a changing marketplace and are pleased that we are in the position to be able to make these strategic investments to further develop our sites and meet these challenges. Individually and collectively, they will help us keep pace with the market and allow us to continue to build a successful future for Vetter and our customers,” said Vetter Managing Director Peter Soelkner. Managing Director Thomas Otto added “As trusted partners for drug product development and manufacturing, it is our intent to always get each customer’s job done right. In order to reach this level on a continuous basis, these investments are the right step, at the right time.”
Vetter is a premier contract development and manufacturing organization (CDMO) and a global leader in the fill and finish of aseptically prefilled syringe systems, cartridges and vials. Headquartered in Ravensburg, Germany, with facilities in Germany and the United States, the company provides state-of-the-art manufacturing, from early clinical development through commercial filling and packaging of parenteral drugs. The CDMO’s extensive experience covers a broad range of complex compounds, including monoclonal antibodies, peptides and interferons. Vetter supports its customers every step of the way, guiding their products through development, regulatory approval, launch and lifecycle management. Known for quality, the company offers a foundation of experience spanning more than 35 years, including dozens of product approvals for novel bio/ pharmaceutical compounds. Since 2014, Vetter operates a representative office in Singapore, increasing the presence of the company and the awareness of its service portfolio in the Asian healthcare market. Visit www.vetter-pharma.com
Vetter Pharma International GmbH
Senior Vice President Key Account Management,
Marketing / Corporate Communications
Phone: +49 (0)751-3700-3729